UK markets close in 7 hours 24 minutes
  • FTSE 100

    6,966.19
    +26.61 (+0.38%)
     
  • FTSE 250

    22,404.57
    +49.12 (+0.22%)
     
  • AIM

    1,245.22
    +1.31 (+0.11%)
     
  • GBP/EUR

    1.1514
    +0.0017 (+0.15%)
     
  • GBP/USD

    1.3787
    +0.0006 (+0.05%)
     
  • BTC-GBP

    45,669.89
    -1,372.70 (-2.92%)
     
  • CMC Crypto 200

    1,377.99
    +2.21 (+0.16%)
     
  • S&P 500

    4,124.66
    -16.93 (-0.41%)
     
  • DOW

    33,730.89
    +53.62 (+0.16%)
     
  • CRUDE OIL

    62.93
    -0.22 (-0.35%)
     
  • GOLD FUTURES

    1,746.20
    +9.90 (+0.57%)
     
  • NIKKEI 225

    29,642.69
    +21.70 (+0.07%)
     
  • HANG SENG

    28,732.33
    -168.50 (-0.58%)
     
  • DAX

    15,257.47
    +48.32 (+0.32%)
     
  • CAC 40

    6,218.38
    +9.80 (+0.16%)
     

Autolus Therapeutics to Participate in Investor Conferences Through April

  • Oops!
    Something went wrong.
    Please try again later.
Autolus Limited
·1-min read
  • Oops!
    Something went wrong.
    Please try again later.

LONDON, April 01, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that management will participate in 1x1’s at investor conferences through April 2021.

  • April 6 and 8, 2021 - Wells Fargo Annual Biotech Corporate Access

  • April 14, 2021 - 20th Annual Needham Virtual Healthcare Conference – As well as 1x1’s, the CEO and CFO will participate in a Fireside Chat at 10:15 AM ET. A webcast of the Fireside Chat will be available on the investor relations section of the Company’s website at Autolus.

  • April 22, 2021 - Raymond James Oncology Summit

  • April 28, 2021 - Kempen & Co. European Life Sciences: Gene, Cell, and RNA Day

About Autolus Therapeutics plc
Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. For more information please visit www.autolus.com.

Contact:

Julia Wilson
+44 (0) 7818 430877
j.wilson@autolus.com

Susan A. Noonan
S.A. Noonan Communications
+1-212-966-3650
susan@sanoonan.com